An automated multi-pumping flow system is proposed for the simultaneous chemiluminometric determination of benserazide and levodopa using multivariate calibration methods. The developed methodology is based on chemiluminescence (CL) emission generated by the reaction of benserazide with luminol, and on a concurrent inhibiting effect of levodopa on this reaction. A multi-pumping flow system comprising multiple solenoid micro-pumps as the only active components was developed to implement a stopped-flow approach for signal acquisition and processing. Artificial neural networks were used to establish a relationship between the CL emission profile and the concentration of both drugs. The concentration values used to establish the experimental calibration samples were varied between 5 and 30 mg l -1 for levodopa and between 2.5 and 20 mg l -1 for benserazide. The proposed method was successfully applied to the simultaneous determination of levodopa and benserazide in pharmaceutical formulations combining both drugs.
Introduction
Levodopa ((-)-3-(3,4-dihydroxyphenyl)-L-alanine) is the immediate precursor of the neurotransmitter dopamine. Unlike dopamine, levodopa easily enters the central nervous system, being used in the treatment of Parkinson's disease, which is associated with dopamine depletion in the brain. However, in a therapeutic regimen high levodopa doses are required, since this is rapidly decarboxilated and very little unchanged drug is available to cross the blood-brain barrier for central conversion into dopamine. Consequently, levodopa is usually associated with a peripheral dopa-decarboxilase inhibitor, such as benserazide ((RS)-2-amino-3-hydroxy-2¢-(2,3,4-trihydroxybenzyl)-propanohydrazide). 1 Hence, for quality control of pharmaceutical formulations it is important to develop a method for the selective simultaneous determination of levodopa and benserazide.
In the literature there are few methods available for the simultaneous determination of levodopa and benserazide. Due to the chemical similarity of the two compounds, simultaneous determination was achieved using differential spectrophotometry, 2 derivative spectrophotometry [3] [4] [5] and kineticspectrophotometric methods. 6, 7 Capillary electrophoresis (CE) with spectrophotometric 8, 9 and amperometric detection 10 was also used for simultaneous determination of these drugs.
Chemiluminescence (CL) has been used for individual levodopa determination by a reaction with potassium permanganate, 11 inhibition of the reaction between luminol and hypochlorite 12 or through the production of hydrogen peroxide by a reaction with imidazole. 13 A CE-CL method, based on the inhibition of the luminol-potassium hexacyanoferrate(III) CL system, was used for the simultaneous determination of levodopa and benserazide. 14 CL is known to be a fast, sensitive and versatile analytical technique; however, a limitation to more widespread applications of direct CL is often poor selectivity because many coexisting substances can react with CL reagents to give the emission of light. The method usually used to solve a lack of selectivity in complex samples is previous separation of the pure compounds prior to analysis; however, the separation conditions are often incompatible with the CL reaction conditions. Thus, another approach is to try to avoid the separation step using chemometric methods to resolve one or more components in mixtures.
In recent years, the combined utilization of flow techniques and multivariate calibration methods was revealed to be a resourceful strategy for multicomponent analysis without prior separation. In this regard, artificial neural networks (ANN) 15 are undergoing a significant application increase in different techniques, including CL, [16] [17] [18] [19] thus confirming their potential as a modelling technique. With appropriate ANN modelling it is often possible to eliminate or reduce the effects of analyteanalyte interactions, synergistic effects, multi-steps processes and any other unknown non-linearity.
The effect of several phenolic compounds on the CL emitted by the oxidation of luminol has been extensively studied. 20, 21 Based on an enhancement of the luminol CL and using the stopped-flow strategy, Díaz and García 22 described the simultaneous determination of two phenolic acids. In the search for a CL method for simultaneous levodopa and benserazide determination, it was observed a CL reaction between benserazide and luminol that was inhibited by the presence of levodopa. Benserazide may be able to reduce the dissolved oxygen to superoxide radical that reacts with luminol yielding the CL emission. 23 The mechanism of inhibition by levodopa is 986 ANALYTICAL SCIENCES AUGUST 2008, VOL. 24 probably related to a competition between levodopa and luminol for superoxide radical. 21 The aim of this work was thus to develop a chemiluminometric methodology for the simultaneous determination of both drugs in pharmaceutical formulations. By combining an automated multi-pumping flow system, used to develop the chemiluminescent reaction and to implement a stopped-flow approach with artificial neural networks, for processing the evolution of the CL response versus time, it was possible to discriminate the concentration of these two compounds. The use of solenoid micro-pumps as the only active components of the flow system, acting simultaneously as solutions insertion, propelling and commuting units, allowed an easier control of transport and stopping of the sample zone, permitting the reproducible monitoring of reaction development. 24, 25 The pulsed flow resultant from the micropumps actuation provided an almost instantaneous mixture of the sample and the reagent, thus allowing the reaction zone to be retained inside the flow cell immediately after mixing, ensuring detection of the entire CL profile.
Experimental

Reagents and chemicals
All chemicals were of analytical grade, and doubly deionized water was used throughout. A 5 ¥ 10 -3 mol l -1 luminol (Sigma, St Louis, MO) stock solution was prepared by dissolving 88.8 mg of the compound in 100 ml of 10 -1 mol l -1 sodium carbonate and kept protected from light.
Then, 300 mg l -1 benserazide hydrochloride (Sigma) and levodopa (Sigma) stock solutions were prepared by dissolving 15 mg of the drugs in 50 ml of deionized water. The benserazide hydrochloride and levodopa stock solutions were kept in a refrigerator and protected from light. Working solutions were prepared daily by rigorous dilution of the stock solution. Sample solutions of commercially available pharmaceutical formulations (Madopar) were prepared by dissolving the required amount in 100 ml of deionized water.
Equipment and software
Chemiluminescence measurements were performed in a Camspec CL-2 (Cambridge, UK) chemiluminescence detector equipped with a 60 ml inner volume quartz flow-cell.
The solenoid micro-pumps, Ref. 090SP (BIOCHEMvalve Inc., Boonton) were of fixed displacement type, dispensing 8 ml per stroke (with deviations of less than 1%) and could be actuated at pulse frequencies as high as 250 min -1 . A CoolDrive TM power drive circuit (NResearch, West Caldwell, NJ) was used to operate the solenoid pumps. Data acquisition and control of the analytical system was accomplished through a PC-LABCard Model PCL-818L interface card from Advantech (Cincinnati, OH) and a 486 DX based microcomputer.
The software was developed in QuickBASIC 4.5.
The flow setup also included flow lines of 0.8 mm i.d. PTFE tubing, end-fittings, connectors and a confluence point.
Data treatment was performed with Matlab version 6.5 (Mathworks) using ANN (Mathworks) and PLS (Eigenvector) toolboxes.
Flow manifold
The developed flow system ( Fig. 1 ) comprised three solenoid micro-pumps (P1 to P3) that were accountable for insertion and propulsion of all involved solutions. P1 was responsible for luminol solution insertion, while P2 and P3 were responsible for sample and carrier insertion, respectively. The pumps acted simultaneously as commuting and propelling devices, controlling at once the sample and reagent volumes, flow rate, timing and sequence of insertion and transportation of the developing reaction zone towards detection.
The analytical cycle started with the activation of P3 in order to propel the carrier solution (deionized water) to the detector for baseline establishment. Thereafter, a given sample volume was inserted by the actuation of P2, while the luminol solution was simultaneously added by means of P1. The sample and luminol zones merged at confluence point X, forming the reaction zone. P3 was then activated for propelling the reaction zone towards detection (P1 and P2 were deactivated). Due to the pulsed nature of the flowing stream, a fast reaction zone homogenization was achieved, and thus the reactor had only the minimum length required to connect the confluence point to the detector. When the reaction zone was inside the flow cell in front of the detector (photomultiplier tube), P3 was deactivated for a pre-defined time interval, and a stopped flow strategy was used to retain the emitting solution in the flow cell in order to obtain the whole profile of the CL intensity versus time. After detection, P3 was activated for system washing.
Data processing
Since there was no a priori knowledge about the reaction mechanism, the obtained data were processed using two multivariate methods, partial least squares (PLS) and artificial neural networks (ANN).
PLS is a statistical multivariate technique used to develop regression models between dependent process variables (e.g., analyte concentration) and a set of independent process derived variables.
It is used when the response-concentration relationship is linear. 26 Feed forward ANN are non-linear mathematical functions applied in the (bio)chemical engineering field to model unknown input-output relationships. 15 For the ANN models, a principal component analysis (PCA) was previously applied, and the obtained components were used as inputs to the neural network. This feature extraction decreases the training time without information loss. The number of principal components was optimized using a cross-validation procedure and the training set. Concentrations for the prediction set were obtained.
For constructing PLS and ANN models, the prediction ability of the models was evaluated in terms of the root mean squared error (RMSE) and the mean relative error (MRE), which can be obtained using the following equations:
In these equations, yi and *i are the real concentration and the predicted model concentration for experiment i, respectively, and n is the total number of experiments. Model errors are divided in calibration and testing errors. Calibration errors are based on a cross-validation strategy, used to optimize the model structure. Testing errors are obtained by using the calibrated models in unseen data, which are obtained from real samples.
In PLS the number of latent variables is optimized by leaveone-out cross-validation from calibration data. 27 For each specific number of latent variables, n models are developed (n being the number of calibration experiments), each one without the ith experiment (i = 1,·, n). Each model is then used to predict the corresponding ith experiment. Predictions are used to compute the RMSE (in this case called RMSECV). The best number of latent variables corresponds to the minimum RMSECV. A final model is then obtained by using all calibration samples and the best number of latent variables. This model is used to predict the testing samples. The RMSE of prediction is also calculated (RMSEP).
Prediction intervals for PLS are obtained after estimating the error standard deviation using a bootstrapping strategy. 28 Consider a data set composed of n experiments. For each sample i (i =1,·, n), several PLS models are calibrated from a set of experiments obtained by sampling with replacement n experiments from the remaining n-1 samples, excluding the test sample. Then, the test sample is projected on each model and prediction residuals are used to estimate the error standard deviation. The latter is used to estimate the prediction confidence limit at a given confidence level, typically 95%. 29, 30 The strategy adopted for neural networks is equivalent to that described for PLS, with some adjustments. In this case, leaveone-out cross-validation is used to optimize the number of hidden nodes. The difference from the PLS strategy is that each trained network depends on a random initialization of parameters (weights and bias). Therefore, 150 networks are trained in each case and predictions are obtained by averaging the individual predictions. From these 150 models, the best 100 models are retained. Therefore, each network prediction is an average of 100 different predictions. This strategy also enables one to estimate the prediction interval for each predicted sample (using the standard deviation of predictions).
Experimental design
To verify the robustness of the analytical procedure, experiments covering a defined concentration range for levodopa and benserazide (5 -30 and 2.5 -20 mg l -1 , respectively) were performed. These concentrations were defined according to the linear-response range of the univariate benserazide calibration, and in order to comprise a ratio of levodopa/benserazide concentrations equal to that found in the pharmaceutical formulations. Because numerous combinations were possible, an experimental design based on maximization of the design matrix determinant (D-optimal design) was used to generate a set of experiments and replicates. A total of 33 experiments were designed, from which 20 were replicates. Replicates were required to analyze the robustness of the experimental procedure. For each experiment, the univariate chemiluminescence signal was acquired over time (from 0 to approximately 90 s).
To evaluate the analytical procedure for the simultaneous quantification of levodopa and benserazide, a calibration set consisting of 16 standards with different concentrations of levodopa (5, ) following a full factorial design ( 4 2 ) was used. A total of 4 calibration sets were performed. These experiments were used to develop multivariate calibration models (external standard calibration) for each molecule. The developed calibration models were tested using real samples of commercial pharmaceuticals (testing experiments). Spiked samples were also analyzed to verify the recovering rates. Table 1 summarizes the conducted experiments.
Results and Discussion
Multivariate calibration methods allow the multicomponent analysis of mixtures without prior separation, using data obtained from spectral analysis of the mixture. In CL analysis the intensity detected is the total intensity at all wavelengths without spectral discrimination to help simultaneous determination. However, if the kinetic characteristics of the analytes in the detection system are different, a mixture of compounds can be solved by using time-intensity curves. By resorting to a stopped-flow strategy, it was possible to retain the emitting solution inside the flow cell, obtaining the CL transient signal. Hence, the flow system was optimized in order to obtain the maximum radiation emission and to detect the whole CL emission against time.
Flow system optimization
Laboratory studies revealed that benserazide generated CL emission with luminol in alkaline solution, and that this reaction was inhibited by levodopa. The presence of levodopa caused not only a decrease of the maximum CL emission, but also affected the rate of decay of the radiation emitted by the reaction of benserazide with luminol.
Because the reaction responsible for CL emission was the reaction between benserazide and luminol, the flow system performance was optimized on the basis of this reaction using pure solutions of benserazide. The luminol concentration was an important parameter, which affected the magnitude of the analytical signal, because luminol was the precursor of the emitting specie. By using luminol solutions at concentrations ranging from 7.5 ¥ 10 -5 to 1.0 ¥ 10 -3 mol l -1 , it was verified that Nevertheless, a concentration of 2.5 ¥ 10 -4 mol l -1 was selected for further work, since it represented a compromise between the sensitivity and luminol consumption. In fact, for 5 ¥ 10 -4 mol l -1 the consumption of luminol almost doubled with only a slight increase in sensitivity.
Considering that luminol oxidation occurred under alkaline conditions, the pH influence was also investigated. With this purpose, different luminol solutions prepared in 10 -1 mol l -1 sodium carbonate with the pH being adjusted between 9.5 and 12 were evaluated. The results showed that the CL intensity was higher for pH 11.5, which was selected for subsequent assays.
In the developed methodology, the sample and luminol solutions were inserted simultaneously in a merging zones strategy. The pulsed flow resultant from micro-pumps actuation promoted an extensive mixture at the point where the confluence of the fluids occurred. This fact was confirmed by a similarity between the analytical signals obtained using the merging zones or binary sampling strategies.
In multi-pumping flow systems, the stroke volume and the number of pulses of micro-pump actuation define the sample and reagent volumes. The influence of the sample volume was studied in the range of 16 to 112 ml, which corresponded to a number of pulses between 2 and 14. It was observed that the CL intensity increased with the sample volume until 96 ml, and then approached stabilization. This value was then selected for further work. As previously referred the sample insertion was carried out by merging zones strategy, thus the reagent volume inserted was the same as the sample volume (96 ml).
The flow rate is a relevant parameter, especially because it determines the time between sample and reagent mixing and detection, conditioning the detected CL intensity. In a multipumping flow system, the flow rate is established in terms of the pulse frequency. The pulse frequency was varied within 60 and 150 pulses per minute, which corresponded to flow rates within 0.48 and 1.2 ml min -1 . The results showed that, with increasing benserazide concentrations, attaining of the maximum CL intensity demanded the utilization of increasing flow rates. This fact is probably related to an increment in the reaction rate, caused by increased benserazide concentrations, which resulted in a fast chemiluminescence response that needed a higher flow rate for adequate maximum CL emission detection. Under these circumstances a flow rate of 0.8 ml min -1 , which represented a compromise between flow rate, benserazide concentration and chemiluminescence intensity, also assuring a wide working range, was selected for subsequent experiments.
The aim of the developed methodology was to evaluate the CL emission variation versus time. Accordingly, the sample zone had to be carried into the flow cell and CL emission had to occur in front of the detector in order to monitor the whole CL profile. In this way, a stopped-flow strategy was implemented to monitor reaction development, functioning as a kinetic method. The sample was carried to detection and retained inside the flow cell, where the CL reaction took place. Considering that the mixing provided by micro-pumps actuation was sufficient to guarantee proper reaction zone homogenization, a reactor was not required for mixing the luminol and the sample. In this way it was possible to use only a very short tubing, with a minimum length to connect the confluence point and the detector.
An important requirement for a reproducible kinetic measurement is an effective control of the transport process and of the sample zone stop interval. In multi-pumping flow systems, the simplicity of the control of the sample transport for detection, based on a pulse-counting routine, facilitates effective monitoring of the position of the sample zone inside the flow system, which permits the application of controlled and reproducible stopping strategies for the flowing stream. The number of pulses required to place the sample zone in front of photomultiplier was evaluated, and it was verified that 6 pulses corresponded to the wider analytical signal. When the sample zone was inside the flow cell, the flow was stopped and CL emission was measured during 90 s until returning to the baseline.
After system optimization, and by using the defined experimental conditions (without the stopped flow strategy) to establish a calibration curve, a linear response for benserazide hydrochloride concentrations of up to 20 mg l -1 (6.8 ¥ 10 -5 mol l 
Chemometric model optimization
Despite the simplicity of the reaction between benserazide and luminol, the presence of levodopa, as it was previously referred, made it difficult to discriminate between the two drugs. Accordingly, after flow system optimization, the next step consisted of the selection and optimization of a chemometric model for levodopa and benserazide simultaneous determination based on the analytical signal attained with the previously defined conditions. CL profiles from dataset #1 solutions were recorded, and it was verified that the profiles corresponding to replicates were almost overlapped (Fig. 2) , indicating that the experimental analytical procedure provided accurate results. Since the nature of the acquired data is multivariate, the unidimensional profiles of the CL experiments from dataset #1 were modelled by principal component analysis (PCA) in order to visualize the relationships among different experiments more easily, while maintaining the same information (e.g., the same original variance). 31 Only data from 24 s was used to build the model, since before 24 s the profiles do not contain important information (the observed variation is due only to noise). The data were mean-centered before PCA modelling. The results showed that 99.5% of the variance was captured by the two first components. The first component accounts for the major part of the data variance (94.7%) while the second component only accounts for 4.8% of the total data variance. Figure 3 shows the two principal components and replicates that were projected onto the model. A similarity between the experiments (filled squares) and corresponding replicates (hollow squares) indicates good reproducibility of the analytical procedure. It is clear from the spatial distribution of the principal components that a pattern exists, and that the chemiluminescence signal is related to the concentrations of benserazide and levodopa. A similar analysis was performed with dataset #2, in which the levodopa and benserazide concentrations were distributed in a grid according to a full factorial design. Data were meancentered and then used to build a PCA model (Fig. 4) allowing the evaluation of the impact of varying the analytes concentrations in the time-based CL signal. Together, the two first principal components account for more than 99% of the total data variance. For better understanding the scores, representing experiments were connected with solid and dotted lines. The solid lines connect experiments with the same benserazide concentration, while dotted lines connect experiments with equal concentrations of levodopa (note here that despite the second component retainining only about 2% of the original data variance, it can be related with an increase in the levodopa concentration, thus also having a chemical meaning). The map produced by the PCA model demonstrates that there are two major sources of variation, which are approximately independent. Roughly, component 1 might be interpreted as being more associated with benserazide and thus the main direction within data, and component 2 with levodopa. Despite the latter evidence, no component can by itself account for the variation of each analyte. However, by accounting for the two components simultaneously, it was clear that the pattern of variation of the two analytes was approximately orthogonal, which indicated that the influence of the components in the chemical reaction, monitored by CL, could be adequately resolved by the principal component analysis model. These results showed that one might be able to infer the concentrations of levodopa and benserazide from the reaction chemiluminescence profiles. The entire chemiluminescence profiles can be used to identify multivariate regression models for levodopa and benserazide modelling. Due to data dimension PLS regression was adopted to model the analytes concentration based on time profiles of CL data. Even though it is possible to build a single PLS model for both analytes simultaneously, it is generally accepted that one model for each analyte is better in terms of the prediction error (bias) and error distribution (variance). 26 Because it was known that PLS models might be very different, depending on the predictors used (in this case the signal measured versus time), the best data window to model the analytes concentration was estimated. The procedure was based on building several models, while considering different time windows of different size using dataset #2. Models were tested, while considering data from 24.5 up to 90 s. For predicting levodopa, a minimum error (RMSECV) of 1.54 was obtained for a time window from 32.2 to 45.1 s (model for 3 latent variables). Similarly, for predicting benserazide, the absolute minimum was found for a window starting at 29.6 s and ending at 68.2 s. For this 2 latent variable model, the error (RMSECV) was 0.69 (see Table 2 ).
Although using PLS yielded a very satisfactory model for benserazide prediction, it was verified that a good fitting for levodopa was not achieved. Models based on feed-forward neural networks were developed for levodopa and benserazide in order to build a comparison, and to evaluate the benefits of a non-linear modelling strategy. Neural network modelling of multiple inputs processes is not a very acceptable procedure, due to an over-fitting risk, since the number of parameters used to adjust is high. In this case, PCA was selected to extract principal components, which were used as inputs to the neural network (entire CL profiles were used to extract the principal components). In all cases, more than 99.5% of the variance was captured by three principal components. A three layered neural network structure was selected as the basic model and for each network the number of nodes in the hidden layer was optimized by cross-validation. Initially, a neural network with linear activation functions in the hidden and output layers was first applied, and compared with PLS, however no significant differences in terms of predictions were observed. A neural network with a non-linear activation function was then tested, using hyperbolic tangent and a linear function as activation functions for hidden nodes and the output node, respectively.
PLS and non-linear neural network models were developed for datasets #2 to #5. The most important parameters for PLS (the number of latent variables) and neural networks (number of hidden layer nodes) were optimized in every case using the cross-validation strategy described before. Model optimization was made purely based on calibration data. Both for PLS and neural networks, the cross-validation errors were based on the leave-one-out strategy. The developed models were tested using unseen data from real samples. Table 2 describes the results obtained from datasets #2 to #5 (external standard experiments) using linear PLS and non-linear neural networks models. As can be seen, the substitution of PLS by neural networks allowed a decrease in the prediction error that was especially important in the case of levodopa. For levodopa, the mean testing error (average over the 4 external standard experiments) with PLS calibration was 9.4%, while for neural networks it was 4.5%. For benserazide, PLS regression was able to provide estimates with approximately 6% relative error and neural networks were able to provide only a marginal improvement to 4.5%. It was confirmed that it was difficult to provide good estimates of levodopa in real samples using the PLS model. This might be explained by the fact that the variation of CL data was primarily due to the variation of benserazide in the concentrations range tested. It was also observed for the case of levodopa that the cross-calibration validation errors were also more severe when compared to benserazide. It could be argued that the lack of a fit of the PLS models for the levodopa in real samples could be due to different matrix effects. In fact, real samples contain more chemical species than levodopa and benserazide, while calibration samples only contain the latter. Therefore, and since PLS with these data cannot use the so-called second-order advantage, 32 interferents in the matrix of real samples could lead to changes in the expected CL profiles. Since these interferents were not accounted for in the calibration, the model would not be adequate. However, this was not verified in the case of neural networks models, which would suffer from the same problem, if it existed. Therefore, the superior performance of neural networks over PLS in the case of levodopa could be due to signal patterns that cannot be explained by PLS.
Interferences
In order to apply the developed methodology to the determination of levodopa and benserazide hydrochloride in pharmaceutical formulations, the interfering effect of several compounds commonly used as excipients was assessed. Samples containing benserazide hydrochloride and levodopa at fixed concentrations of 1.0 ¥ 10 -4 and 1.7 ¥ 10 -5 mol l -1 , respectively, and increasing concentrations of the excipient were analyzed by the developed method.
A compound was considered as non-interfering if the analytical signal variation was ±3% when compared to the analytical signal obtained in the absence of the referred compound. By assaying up to 100:1 (excipient:levodopa) molar ratio, it was observed that compounds, such as citric acid, glucose, galactose, sucrose, manitol and magnesium stearate did not interfere. Gelatine interfered for a molar ratio up 10:1 (excipient:levodopa). Since the average mass of the tablets is two-times the mass of levodopa and benserazide present, none of the excipients tested were present in a concentration that would cause interference.
Pharmaceutical formulations analysis
Aiming to evaluate the developed methodology performance, the described multi-pumping flow system was applied to the analysis of pharmaceutical formulations containing levodopa and benserazide. The obtained data were processed by the optimized ANN model.
To the best of the authors' knowledge, there is no reference method for levodopa and benserazide simultaneous determination, and therefore the accuracy of the results obtained with the proposed procedure was assessed through recovery tests. A given amount of levodopa and benserazide was added to solutions of different pharmaceutical formulations; the results are given in Table 3 .
The sampling rate was about 28 determinations per hour, and the reagent consumption was 4.3 mg of luminol per determination.
Conclusions
A methodology for the simultaneous determination of levodopa and benserazide with CL detection was proposed. The developed procedure was based on a novel chemical pathway involving the reaction of benserazide with luminol and the inhibiting effect on this reaction provided by levodopa.
To automate this determination and to apply it to the simultaneous determination of levodopa and benserazide in pharmaceutical formulations without previous separation, a multi-pumping flow system was implemented and combined with ANN calibration. The versatility and simplicity of operation of the developed multi-pumping flow system allowed the easy implementation of a stopped flow strategy permitting acquisition of the CL profiles used in the chemometric models. PLS and ANN models were used to process the acquired data, with the best results being provided by ANN. The proposed procedure was sensitive, precise and accurate, constituting an advantageous alternative to the scarce methods available for the simultaneous determination of levodopa and benserazide.
The developed flow approach is fully automated, presents a very low sample and reagent consumption, produces a reduced volume of effluents (about 0.5 ml per determination), and is faster than the other methods described in the literature, even when compared to the flow methodologies already available for simultaneous determination of levodopa and benserazide. 5, 6 Comparatively to the previously reported CE-CL method, 14 the developed method presents a narrower linear range; however, it is simpler, not requiring previous separation which results in a higher sampling rate.
